Drugs & Therapy Perspectives

, Volume 18, Issue 2, pp 8–11 | Cite as

ACE inhibitors still pivotal in the management of proteinuric nephropathies

Disease Management
  • 9 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pisoni R, Ruggenenti P, Remuzzi G. Renoprotective therapy in patients with nondiabetic nephropathies. Drugs 2001: 61 (6): 733–45PubMedCrossRefGoogle Scholar
  2. 2.
    Incidence and prevalence of ESRD. United States Renal Data System. Am J Kidney Dis 1998; 32 (2 Suppl. 1): S38–49Google Scholar
  3. 3.
    Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15PubMedCrossRefGoogle Scholar
  4. 4.
    GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–63CrossRefGoogle Scholar
  5. 5.
    Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Modification of Diet in Renal Disease. Ann Intern Med 1995; 123: 754–62PubMedGoogle Scholar
  6. 6.
    Mallick NP, Short CD, Hunt LP. How far since Ellis? Nephron 1987; 46: 113–24PubMedCrossRefGoogle Scholar
  7. 7.
    Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267–73PubMedCrossRefGoogle Scholar
  8. 8.
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45PubMedCrossRefGoogle Scholar
  9. 9.
    Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999; 10: 997–1006PubMedGoogle Scholar
  10. 10.
    Ruggenenti P, Perna A, Zoccali C, et al. Chronic proteinuric nephropathies. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to ACE gene polymorphism. J Am Soc Nephrol 2000; 11: 88–96PubMedGoogle Scholar
  11. 11.
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Arch Intern Med 2000; 160: 685–93PubMedCrossRefGoogle Scholar
  12. 12.
    Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889–96PubMedCrossRefGoogle Scholar
  13. 13.
    Zoccali C, Valvo E, Russo D, et al. Antiproteinuric effect of losartan in patients with chronic renal diseases [letter]. Nephrol Dial Transplant 1997; 12: 234–5PubMedCrossRefGoogle Scholar
  14. 14.
    Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851–6PubMedCrossRefGoogle Scholar
  15. 15.
    Bakris GL, Weir MR, De Quattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–9PubMedCrossRefGoogle Scholar
  16. 16.
    Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9: 2308–17PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations